Skip to Main Content

Paper Details

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Cell
371
2018
Author NameAffiliation
Yi-Mi WuMichigan Center for Translational Pathology, University of Michigan ann arbor
Marcin CieslikMichigan Center for Translational Pathology, University of Michigan ann arbor
Robert J LonigroMichigan Center for Translational Pathology, University of Michigan ann arbor
Pankaj VatsMichigan Center for Translational Pathology, University of Michigan ann arbor
Pankaj VatsMichigan Center for Translational Pathology, University of Michigan ann arbor
Melissa A ReimersUniversity of Michigan ann arbor
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan ann arbor
Lakshmi P KunjuMichigan Center for Translational Pathology, University of Michigan, USA Rogel Cancer Center ann arbor
Elisabeth I HeathWayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute
Jonathan ChouUniversity of California at San Francisco
Felix Y FengUniversity of California at San Francisco, USA Helen Diller Family Comprehensive Cancer Center
Peter S NelsonFred Hutchinson Cancer Research Center, University of Washington, USA Division of Clinical Research
Peter S NelsonFred Hutchinson Cancer Research Center, University of Washington, USA Division of Clinical Research
Johann S de BonoDivision of Clinical Studies, The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust
Bruce MontgomeryUniversity of Washington
Dan R RobinsonMichigan Center for Translational Pathology, University of Michigan ann arbor
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, USA Rogel Cancer Center, USA Howard Hughes Medical Institute ann arbor
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, USA Rogel Cancer Center, USA Howard Hughes Medical Institute ann arbor
  • 1 - 18

Datasets